Institutional 13F · Context Only · Never a Buy List机构 13F · 仅供参考 · 非买入清单
Casdin Capital
sector_healthcare
A
Reliability improving可靠性走强
leaderboard rank榜单排名 #3WATCH观察
Book持仓规模
$2.0B
long US listed only仅美股多头
Positions持仓数
43
98% resolved已解析
Top-10 concentration前十集中度
77%
% of book占组合%
Turnover换手
LOW
18.2% per quarter每季
Median excess中位超额
+5%
buys vs SPY, since filing买入相对SPY，自披露起 · n 96
Hit rate胜率
55%
share of buys beating SPY跑赢SPY的买入占比
Core lean — the 10-second read核心倾向 — 10秒速读
Core lean: GLP-1 & Obesity — added SRRK (+1.8pp of book this quarter)核心倾向：GLP-1 与减肥药 — 本季度加仓 SRRK（占组合 +1.8pp）
GLP-1 & ObesityGLP-1 与减肥药
+1.8pp
6.2% of book held占组合持有
· 3 names标的
· Healthcare
SRRK
Descriptive read of the latest filing — themes clustered from curated baskets (Finviz fallback), added-pp = Σ % of book bought this quarter. Not a forecast.基于最新披露的描述性解读——主题按精选篮子聚类（Finviz 兜底），added-pp = 本季度买入占组合百分比之和。非预测。
Grade & excess history评级与超额历史
per-quarter buy cohorts, scored on public filing dates vs SPY — descriptive ranks in a curated survivor cohort按季度买入队列，以公开披露日为锚相对SPY评分——精选幸存者队列中的描述性排名Reliability可靠性: improving走强 · 13 scored quarters已评分季度 · 38% positive为正 · recent-4 median近4季中位 +4% vs all-time对全期 -9%
Median excess by quarter各季度中位超额: ▁▃▃█▃▃▃▅▃▃▄▃ (oldest → newest, shifted by the series minimum so negatives render由旧到新，按序列最小值平移以呈现负值)
| Quarter季度 | Buys买入数 | Median excess中位超额 | Hit胜率 | Median fwd 63d中位前瞻63日 |
|---|---|---|---|---|
| 2023-06-30 | 4 | -76% | 25% | -30% |
| 2023-09-30 | 5 | -95% | 40% | +15% |
| 2023-12-31 | 5 | -9% | 40% | +11% |
| 2024-03-31 | 6 | -15% | 50% | -11% |
| 2024-06-30 | 5 | +143% | 100% | +2% |
| 2024-09-30 | 8 | -5% | 50% | +19% |
| 2024-12-31 | 7 | -14% | 43% | -25% |
| 2025-03-31 | 7 | -25% | 43% | -8% |
| 2025-06-30 | 4 | +58% | 75% | +55% |
| 2025-09-30 | 6 | -9% | 33% | +9% |
| 2025-12-31 | 16 | +3% | 56% | -6% |
| 2026-03-31 | 12 | +18% | 67% | +14% |
| 2026-06-30 | 11 | +6% | 73% | — |
Sector exposure & rotation行业配置与轮动
value-weighted, latest filing; QoQ deltas vs prior quarter按市值加权，最新披露；季度环比变化对上季Current weights当前权重 · 2026-06-30
Healthcare
96.9%
▲ +0.3pp
Unclassified
3.1%
▼ -0.3pp
Theme categories主题类别
Healthcare 6.2%
US Sectors (EW) 0.8%
Rotating into (QoQ)轮入（环比）
Healthcare +0.3pp
Rotating out of (QoQ)轮出（环比）
no QoQ decreases无环比减持
Quarter history — top-3 sectors季度历史 — 前三大行业
| 2026-06-30 | Healthcare 97% · Unclassified 3% · |
| 2026-03-31 | Healthcare 97% · Unclassified 3% · |
| 2025-12-31 | Healthcare 95% · Unclassified 5% · |
| 2025-09-30 | Healthcare 93% · Unclassified 7% · Basic Materials 0% |
| 2025-06-30 | Healthcare 91% · Unclassified 9% · Basic Materials 0% |
| 2025-03-31 | Healthcare 89% · Unclassified 10% · Basic Materials 1% |
| 2024-12-31 | Healthcare 89% · Unclassified 8% · Basic Materials 2% |
| 2024-09-30 | Healthcare 86% · Unclassified 11% · Basic Materials 3% |
| 2024-06-30 | Healthcare 84% · Unclassified 14% · Basic Materials 2% |
| 2024-03-31 | Healthcare 82% · Unclassified 15% · Basic Materials 3% |
| 2023-12-31 | Healthcare 79% · Unclassified 18% · Basic Materials 3% |
| 2023-09-30 | Healthcare 66% · Unclassified 31% · Basic Materials 3% |
Full book完整持仓
every resolved position as filed — click a column header to sort. Conviction is a descriptive composite, not a forecast.截至披露日的全部已解析持仓——点击列头排序。信念分为描述性综合指标，非预测。42 positions shown项持仓 · resolved已解析 42/43 (98%) · unresolved CUSIPs are excluded from this table but counted in book totals未解析CUSIP不列入本表，但计入组合总额
| #↕ | Ticker标的 ↕ | Company公司 ↕ | % book仓位% ↕ | Value金额 ↕ | Action动作 ↕ | Δ sharesΔ股数 ↕ | Add streak连加季数 ↕ | Conviction信念分 ↕ | Sector行业 ↕ | Themes主题 | Since filing自披露 ↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |  RVMD |
Revolution Medicines Inc | 24.2% | $483M | hold | +0% | — | 70 · HIGH | Healthcare | — | -1% |
| 2 |  RLAY |
Relay Therapeutics Inc | 15.0% | $300M | add | +11% | 3q | 84 · HIGH | Healthcare | — | -8% |
| 3 |  WGS |
Genedx Holdings Corp | 12.7% | $254M | add | +23% | 1q | 73 · HIGH | Healthcare | — | +10% |
| 4 |  BLFS |
Biolife Solutions Inc | 6.6% | $131M | trim | -22% | — | 68 · MODERATE | Healthcare | — | -0% |
| 5 |  ILMN |
Illumina Inc | 4.7% | $93M | hold | +0% | — | 67 · MODERATE | Healthcare | Oncology, Diagnostics, Genomics | +9% |
| 6 |  LAB |
Standard Biotools Inc | 3.7% | $73M | hold | +0% | — | 66 · MODERATE | Healthcare | — | +2% |
| 7 |  GPCR |
Structure Therapeutics Inc | 3.2% | $63M | hold | +0% | — | 65 · MODERATE | Healthcare | GLP-1 & Obesity | -27% |
| 8 |  DNLI |
Denali Therapeutics Inc | 2.6% | $53M | add | +11% | 1q | 69 · MODERATE | Healthcare | — | -12% |
| 9 |  NGNE |
Neurogene Inc | 2.4% | $49M | hold | +9% | — | 63 · MODERATE | Healthcare | — | — |
| 10 |  BEAM |
Beam Therapeutics Inc | 2.3% | $46M | hold | +0% | — | 52 · MODERATE | Healthcare | Next-Gen | -10% |
| 11 |  TXG |
10x Genomics Inc | 2.0% | $40M | trim | -54% | — | 37 · LOW | Healthcare | Diagnostics, Genomics | +16% |
| 12 | SRRK |
Scholar Rock Hldg Corp | 1.8% | $37M | add | +90% | 3q | 51 · MODERATE | Healthcare | GLP-1 & Obesity | +1% |
| 13 |  PSNL |
Personalis Inc | 1.7% | $34M | add | +59% | 2q | 45 · MODERATE | Healthcare | — | +19% |
| 14 |  GRAL |
Grail Inc | 1.6% | $33M | add | +109% | 2q | 44 · LOW | Healthcare | — | +10% |
| 15 |  GH |
Guardant Health Inc | 1.4% | $28M | trim | -41% | — | 33 · LOW | Healthcare | Oncology, Diagnostics, Genomics | +5% |
| 16 |  MAZE |
Maze Therapeutics Inc | 1.3% | $25M | add | +11% | 1q | 38 · LOW | Healthcare | — | — |
| 17 |  HIMS |
Hims & Hers Health Inc | 1.2% | $24M | hold | +0% | — | 32 · LOW | Healthcare | GLP-1 & Obesity | +2% |
| 18 |  ALNY |
Alnylam Pharmaceuticals Inc | 1.1% | $23M | hold | +0% | — | 31 · LOW | Healthcare | Next-Gen | +12% |
| 19 |  TSHA |
Taysha Gene Therapies Inc | 1.1% | $22M | hold | +0% | — | 30 · LOW | Healthcare | — | -15% |
| 20 |  AGMB |
Agomab Therapeutics Nv | 1.0% | $20M | hold | +0% | — | 29 · LOW | — | — | — |
| 21 |  SEPN |
Septerna Inc | 0.9% | $19M | hold | +0% | — | 28 · LOW | Healthcare | — | -13% |
| 22 |  PBLS |
Parabilis Medicines Inc | 0.9% | $18M | new | — | 1q | 22 · LOW | — | — | +5% |
| 23 |  SION |
Sionna Therapeutics Inc | 0.9% | $18M | new | — | 1q | 22 · LOW | Healthcare | — | +28% |
| 24 |  VCYT |
Veracyte Inc | 0.8% | $16M | hold | +0% | — | 26 · LOW | Healthcare | — | -1% |
| 25 |  ANL |
Adlai Nortye Ltd | 0.7% | $14M | add | +132% | 2q | 35 · LOW | — | — | — |
| 26 |  PRME |
Prime Medicine Inc | 0.6% | $12M | hold | +0% | — | 24 · LOW | Healthcare | — | — |
| 27 |  ABSI |
Absci Corporation | 0.6% | $11M | hold | +0% | — | 23 · LOW | Healthcare | — | -9% |
| 28 |  DGX |
Quest Diagnostics Inc | 0.5% | $11M | hold | +0% | — | 22 · LOW | Healthcare | Health Care (Equal-Weight) | +3% |
| 29 |  SRPT |
Sarepta Therapeutics Inc | 0.4% | $8M | new | — | 1q | 27 · LOW | Healthcare | — | +15% |
| 30 |  NTLA |
Intellia Therapeutics Inc | 0.3% | $6M | hold | +0% | — | 21 · LOW | Healthcare | Next-Gen, Genomics | +6% |
| 31 |  MRNA |
Moderna Inc | 0.3% | $5M | hold | +0% | — | 20 · LOW | Healthcare | Health Care (Equal-Weight) | +119% |
| 32 |  IRON |
Disc Medicine Inc | 0.2% | $5M | hold | +0% | — | 19 · LOW | Healthcare | — | -1% |
| 33 |  GLUE |
Monte Rosa Therapeutics Inc | 0.2% | $5M | hold | +0% | — | 18 · LOW | Healthcare | — | -7% |
| 34 |  IPSC |
Century Therapeutics Inc | 0.1% | $3M | hold | +0% | — | 18 · LOW | Healthcare | — | +9% |
| 35 |  CTNM |
Contineum Therapeutics Inc | 0.1% | $2M | hold | +0% | — | 17 · LOW | Healthcare | — | — |
| 36 |  BBOT |
Bridgebio Oncology Therapeut | 0.1% | $2M | hold | +0% | — | 16 · LOW | — | — | — |
| 37 |  EDIT |
Editas Medicine Inc | 0.1% | $1M | new | — | 1q | 10 · LOW | Healthcare | — | -4% |
| 38 |  PACB |
Pacific Biosciences Calif In | 0.1% | $1M | hold | +0% | — | 14 · LOW | Healthcare | Diagnostics, Genomics | +8% |
| 39 |  KARD |
Kardigan Inc | 0.1% | $1M | new | — | 1q | 9 · LOW | — | — | +6% |
| 40 |  RXRX |
Recursion Pharmaceuticals In | 0.0% | $606735 | hold | +0% | — | 12 · LOW | Healthcare | Applications | +5% |
| 41 |  DNA |
Ginkgo Bioworks Holdings Inc | 0.0% | $361646 | hold | +0% | — | 12 · LOW | Healthcare | Alt Protein | -1% |
| 42 |  TNYA |
Tenaya Therapeutics Inc | 0.0% | $267531 | hold | +0% | — | 11 · LOW | — | — | — |
Rotation detail轮动明细
this filing cycle, uncapped — adds/new and trims from the resolved book, exits from the rotation feed本披露周期，不设上限——新建/加仓与减持取自已解析持仓，清仓取自轮动数据Rotated into轮入 (13)
| RLAY add |
15.0% | -8% |
| WGS add |
12.7% | +10% |
| DNLI add |
2.6% | -12% |
| SRRK add |
1.8% | +1% |
| PSNL add |
1.7% | +19% |
| GRAL add |
1.6% | +10% |
| MAZE add |
1.3% | — |
| PBLS new |
0.9% | +5% |
| SION new |
0.9% | +28% |
| ANL add |
0.7% | — |
| SRPT new |
0.4% | +15% |
| EDIT new |
0.1% | -4% |
| KARD new |
0.1% | +6% |
Rotated out of轮出 (5)
| BLFS trim |
-22% | -0% |
| TXG trim |
-54% | +16% |
| GH trim |
-41% | +5% |
 MLTX exit |
-100% | -8% |
 TEM exit |
-100% | +22% |
Trade log交易记录
last 40 graded trades, filing-date anchored, newest first — variable hold vs SPY最近40笔已评分交易，以披露日为锚，最新在前——持有期不定，相对SPYNo graded trades available for this fund.该基金暂无已评分交易。
Caveats注意事项 —
13F = quarterly, ~45-day lag, reported long positions from managers with at least $100M in Section 13(f) securities. No shorts, no cash, no non-US positions. This desk is context — ownership is never a directional signal here.13F = 季度披露，约45天滞后，仅含美股多头且持仓≥1亿美元。不含空头、现金或非美股仓位。本台仅为背景参考——持仓数据在此永远不是方向性信号。
Grades and reliability are descriptive ranks within a curated survivor cohort — they measure what filings did after their filing dates, not a manager-selection edge. Conviction and core-lean reads are descriptive composites earning a forward record via the pre-registered ledger (L5); sector/theme classification applies the current map to history.评级与可靠性为精选幸存者队列中的描述性排名——衡量披露日之后持仓的表现，而非经理选择能力。信念分与核心倾向为描述性综合指标，通过预注册账本（L5）积累前瞻记录；行业/主题分类将当前映射应用于历史。